Synlogic Provides Summary of Impact of COVID-19 on Clinical Program Progress and Operational Activities

Living medicines

Home » Health and medicine » Living medicines » Page 2

Synlogic Announces Appointments of New CMO, Head of Regulatory Affairs, and CFO Departure

BiomX Announces In-house Phage Manufacturing Facility

Azitra, Inc. Appoints Mark Sampson, Ph.D. as Chief Scientific Officer

Synlogic Discontinues Development of SYNB1020 to Treat Hyperammonemia

Synlogic Reports Second Quarter 2019 Financial Results and Provides Program Updates

Synlogic Reports Positive Top-line Data from Phase 1/2a Study of SYNB1618 in Patients with Phenylketonuria and Guides to Next Phase of Development

Azitra Receives Ongoing Support for Its Netherton Development Program from the National Science Foundation (NSF)

Azitra Demonstrates Feasibility of Engineering the Skin Microbiome to Treat Serious Skin Conditions

Pieter Rottiers

ActoBio Therapeutics™ CEO Pieter Rottiers on the potential to cure disease with living medicines

Jim Collins

Why now is the time for programmable living medicines: insights from Jim Collins, Aoife Brennan, and Jason Kelly